Edition:
United States

People: Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

72.78USD
7 Dec 2016
Change (% chg)

-- (--)
Prev Close
$72.78
Open
--
Day's High
--
Day's Low
--
Volume
14
Avg. Vol
9,744,716
52-wk High
$104.79
52-wk Low
$71.39

Alton, Gregg 

Mr. Gregg H. Alton is Executive Vice President - Corporate and Medical Affairs of Gilead Sciences Inc. Mr. Alton joined us in 1999, and served as General Counsel from 2000 to 2009, when he was appointed to his current position. In his current role, Mr. Alton is responsible for legal affairs, government affairs, medical affairs, public affairs and emerging market activities. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the boards of the AIDS Institute, the Boys and Girls Clubs of Oakland and Celladon Corporation. He is also a member of the U.S. Government’s Industry Trade Advisory Committee on Intellectual Property Rights, the advisory boards of UCSF Global Health Sciences, USC Schaeffer Center for Health Policy and Economics, Pharmozyme, Inc. and the Dean’s Advisory Council at Stanford Law School. In addition, he serves on Partners In Health’s Board of Trustees. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University.

Basic Compensation

Total Annual Compensation, USD 2,018,980
Restricted Stock Awards, USD 2,159,150
Long-Term Incentive Plans, USD --
All Other, USD 1,757,650
Fiscal Year Total, USD 5,935,780

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 572,000 36,592,200.00
Name Fiscal Year Total

John Martin

18,756,000

John Milligan

8,276,700

Robin Washington

5,557,230

Kevin Young

5,394,710

Norbert Bischofberger

6,953,070

Kathleen Watson

--
As Of  30 Dec 2015